PMV closes $50M offering; rezatapopt data posted for ENA 2026
PMV Pharmaceuticals reported Q3 2026 results, closing a $50 million public offering and revealing interim data showing 46% ORR for rezatapopt in ovarian cancer ahead of an NDA submission in 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed